FDA Grants ALung Emergency Use Authorization (EUA) to the Hemolung® Respiratory Assist System (RAS) for the Treatment of COVID-19

The Hemolung® RAS is currently being used in the FDA approved VENT-AVOID trial for the study of ECCO₂R in the treatment of Acute Exacerbation of Chronic Obstructive Pulmonary Disease (AE-COPD). In addition, the Hemolung RAS and ECCO₂R have been studied for the treatment of moderate to severe Acute Respiratory Distress Syndrome (ARDS) in the just concluded UK REST trial, which enrolled 412 patients.

A public health emergency related to COVID-19 was declared by the Secretary of Health and Human Services (HHS) on February 4, 2020. The FDA has issued an EUA for the Hemolung RAS to treat lung failure caused by COVID-19. As indicated in the FDA’s EUA letter to ALung, the Hemolung RAS is not FDA-cleared or approved, and there are no FDA-approved or cleared device treatments for lung failure caused by COVID-19. ALung submitted and the FDA reviewed in vitro and in vivo information in support of ALung’s ongoing U.S. VENT-AVOID clinical trial for the Hemolung RAS as well as additional information about clinical use of the Hemolung RAS outside the U.S., and additional biocompatibility, cytotoxicity, and performance testing.

Based on the information submitted, the FDA stated that it believes the Hemolung RAS has the potential to treat lung failure as an adjunct to noninvasive or invasive mechanical ventilation, to reduce hypercapnia and hypercapnic acidosis due to COVID-19, and/or to maintain normalized levels of partial pressure of carbon dioxide(PCO₂) and pH in patients suffering from acute, reversible respiratory failure due to COVID-19 for whom ventilation of CO₂ cannot be adequately, safely, or tolerably achieved and, in turn, may provide clinical benefit, and that there is no adequate, approved and available alternative to the emergency use of the Hemolung RAS to treat lung failure caused by COVID-19.

“We are pleased with the FDA’s recognition that the Hemolung may be beneficial in the treatment of COVID-19 by removal of CO₂ directly from the blood during extracorporeal therapy,” said Mr. Peter M. DeComo, Chairman and CEO of ALung Technologies.

Mr. DeComo further stated, “With published mortality rates as high as 90% for patients receiving invasive mechanical ventilation (IMV), we believe that the Hemolung can be a valuable tool for physicians to be used in conjunction with IMV, by reducing or eliminating the potential of further lung damage caused by high ventilator driving pressures, often referred to as Ventilator Induced Lung Injury (VILI). Many of the academic medical centers involved with our clinical trial have already requested the use of the Hemolung RAS for treatment of their COVID-19 patients.”

About ALung Technologies

ALung Technologies, Inc. is a privately held Pittsburgh-based developer and manufacturer of innovative lung assist devices. Founded in 1997 as a spin-out of the University of Pittsburgh, ALung has developed the Hemolung RAS as a dialysis-like alternative or supplement to mechanical ventilation. ALung is backed by Philips, UPMC Enterprises, Abiomed, The Accelerator Fund, Allos Ventures, Birchmere Ventures, Blue Tree Ventures, Eagle Ventures, Riverfront Ventures, West Capital Advisors, and other individual investors.

For more information about ALung and the Hemolung RAS, visit www.alung.com.

For more information on the VENT-AVOID trial, and a list of enrolling sites, please visit clinicaltrials.gov.

For more information on the use of the Hemolung RAS for COVID-19 patients, please visit https://www.alung.com/covid-19/covid-19-us/

*The Hemolung RAS has not been FDA cleared or approved.

*The Hemolung RAS has been authorized for the above emergency use by FDA under an EUA.

*This device is authorized only for the duration of the declaration that circumstances exist justifying the authorization of the emergency use of the Hemolung RAS under Section 564(b)(1) of the Act, 21 U.S.C. § 360bbb- 3(b)(1), unless the authorization is terminated or revoked sooner.

This press release may contain forward-looking statements, which, if not based on historical facts, involve current assumptions and forecasts as well as risks and uncertainties. Our actual results may differ materially from the results or events stated in the forward-looking statements, including, but not limited to, certain events not within the Company’s control. Events that could cause results to differ include failure to meet ongoing developmental and manufacturing timelines, changing GMP requirements, the need for additional capital requirements, risks associated with regulatory approval processes, adverse changes to reimbursement for the Company’s products/services, and delays with respect to market acceptance of new products/services and technologies. Other risks may be detailed from time to time, but the Company does not attempt to revise or update its forward-looking statements even if future experience or changes make it evident that any projected events or results expressed or implied therein will not be realized.

View source version on businesswire.com: https://www.businesswire.com/news/home/20200424005334/en/